Nocturne GmbH
About
Nocturne GmbH develops AI-powered retinal imaging biomarkers that enhance CNS drug development. Our device-agnostic platform standardizes OCT data quality and extracts advanced structural features linked to neuroinflammation, axonal loss, and neurodegeneration.
We help pharma improve trial enrichment, patient stratification, and early signal detection—either through analysis of existing datasets or integration into ongoing studies. Nocturne also co-develops exploratory and secondary imaging endpoints to support biomarker strategies in NMOSD, MS, and Alzheimer’s disease.
We welcome collaborations with companies aiming to accelerate development through reliable, scalable, and non-invasive retinal biomarkers.
Technology
Disease Area
Biomedical Research, Medicine, Human Health
Representatives
CEO
Nocturne GmbH